Effects of Melatonin Combined with Cisplatin on Proliferation, Apoptosis and Invasion of Cervical Cancer HeLa Cells

doi:10.19586/j.2095-2341.2022.0099

Current Biotechnology ›› 2023, Vol. 13 ›› Issue (2): 311-317.DOI: 10.19586/j.2095-2341.2022.0099

• Articles • Previous Articles

Effects of Melatonin Combined with Cisplatin on Proliferation, Apoptosis and Invasion of Cervical Cancer HeLa Cells

Yunyan SHEN(), Qi QIU()

Out-patient Office，the Second Affiliated Hospital of Soochow University，Jiangsu Suzhou 215004，China

Received:2022-06-10 Accepted:2022-10-09 Online:2023-03-25 Published:2023-04-07
Contact: Qi QIU

Abstract

Abstract:

The aim of this study is to explore the effects of melatonin （MLT） combined with cisplatin （DDP） on the proliferation， apoptosis and invasion of cervical cancer HeLa cells. The cervical cancer HeLa cells were cultured in vitro. The effects of MLT， DDP and their combination on the proliferation of HeLa cells were detected by methyl thiazolyl tetrazolium （MTT） method. HeLa cells were divided into control group， melatonin group， cisplatin group and combination group. The melatonin group was treated with 2.5 mmol·L^-1 melatonin， cisplatin group was treated with 5 μg·mL^-1 cisplatin， and combination group was treated with 2.5 mmol·L^-1 melatonin and 5 μg·mL^-1 cisplatin. The proliferation， apoptosis and invasion of HeLa cells were detected by clone formation assay， flow cytometry， scratch assay and Transwell chamber assay， respectively. The expressions of Ki-67， PCNA， Bcl-2， Bax， N-cadherin， E-cadherin and Vimentin were detected by Western blot. MTT results showed that both MLT and DDP could significantly inhibit the proliferation of HeLa cells （P<0.05）， and the inhibition rate was significantly increased with the increase of their concentration （P<0.05）. Compared with MLT and DDP alone， their combination could significantly increased inhibition rate of HeLa cells proliferation. Compared with control group， clone formation rate， number of invaded cells per unit area， scratch healing rate， and related expression levels of Ki67， PCNA， Bcl-2 and E-cadherin proteins were decreased （P<0.05）， while apoptosis rate and relative expression levels of Bax， N-cadherin and Vimentin proteins were increased in melatonin group and cisplatin group （P<0.05）. Compared with melatonin group and cisplatin group， clone formation rate， number of invaded cells per unit area， scratch healing rate， and relative expression levels of Ki67， PCNA， Bcl-2 and E-cadherin proteins were decreased （P<0.05）， while apoptosis rate and relative expression levels of Bax， N-cadherin and Vimentin proteins were increased in combination group （P<0.05）. Results showed that， both MLT and DDP could inhibit the proliferation and invasion of HeLa cells， and promoted their apoptosis， the effects of their combination were more significant.

Key words: cervical cancer, melatonin, cisplatin, HeLa cell, cell proliferation, apoptosis

CLC Number:

R737.33

Yunyan SHEN, Qi QIU. Effects of Melatonin Combined with Cisplatin on Proliferation, Apoptosis and Invasion of Cervical Cancer HeLa Cells[J]. Current Biotechnology, 2023, 13(2): 311-317.

Add to citation manager EndNote|Ris|BibTeX

URL: https://swjsjz.magtechjournal.com/EN/10.19586/j.2095-2341.2022.0099

https://swjsjz.magtechjournal.com/EN/Y2023/V13/I2/311

Figures/Tables 7

References 24

1	MALMQVIST J, SIERSMA V, BANG C W, et al.. Consequences of screening in cervical cancer: development and dimensionality of a questionnaire[J]. BMC Psychol., 2021, 9(1): 7-22.
2	杜巧红, 吴瑞丽, 廉莉. 全面护理干预在80例宫颈癌放疗患者中的应用观察[J]. 中国药物与临床, 2019, 19(10): 1730-1732.
3	KUMAR L, HARISH P, MALIK P S, et al.. Chemotherapy and targeted therapy in the management of cervical cancer[J]. Curr. Probl. Cancer., 2018, 42(2): 120-128.
4	KENMOTSU H, YAMAMOTO N, YAMANAKA T, et al.. Randomized phase Ⅲstudy of pemetrexed plus cisplatin versus vinorelbine plus cisplatin for completely resected stage Ⅱto ⅢA nonsquamous non-small-cell lung cancer[J]. J. Clin. Oncol., 2020, 38(19): 2187-2196.
5	TALIB W H. Synergistic effect of thymoquinone and melatonin against breast cancer implanted in mice[J]. J. Cancer Res. Thera., 2018, 14(1): 324-329.
6	ZOU Z W, LIU T, LI Y, et al.. Melatonin suppresses thyroid cancer growth and overcomes radioresistance via inhibition of p65 phosphorylation and induction of ROS[J]. Redox. Biol., 2018, 16(8): 226-236.
7	ZHENG H F, KYUNG H J, HONG H Y, et al.. Melatonin synergizes with sorafenib to suppress pancreatic cancer via melatonin receptor and PDGFR-β/STAT3 pathway[J]. Cell Physiol. Biochem., 2018, 4(5)1751-1768.
8	YU Z, TIAN X, PENG Y, et al.. Mitochondrial cytochrome P450 (CYP) 1B1 is responsible for melatonin‐induced apoptosis in neural cancer cells[J]. J. Pin. Res., 2018, 5(5): 12478-12485.
9	HUANG L L, RAO W. SiRNA interfering STAT3 enhances DDP sensitivity in cervical cancer cells[J]. Eur. Rev. Med. Pharmacol. Sci., 2018, 22(13): 4098-4106.
10	杜春双, 王帅, 张飞,等. 左旋紫草素联合顺铂对宫颈癌Hela细胞的抑制作用及其作用机制[J]. 沈阳药科大学学报, 2018, 35(3): 232-237.
11	JIN Y, LV L, NING S X, et al.. The anti-tumor activity and mechanisms of rLj-RGD3 on human laryngeal squamous carcinoma Hep2 Ccells[J]. Anticancer Agents. Med. Chem., 2019, 19(17): 2108-2119.
12	ZIŃCZUK J, ZARĘBA Z, GUZIŃSKA-USTYMOWICZ K, et al.. Expression of chosen cell cycle and proliferation markers in pancreatic intraepithelial neoplasia[J]. Prz. Gastroenterol., 2018, 13(2): 118-126.
13	杨松, 魏风, 刘海峰. 颅内良性脑膜瘤全切术后复发的临床病理特征及血管内皮生长因子、细胞周期相关核抗原Ki-67抗体和p53的表达分析[J]. 中国肿瘤临床与康复, 2019, 26(4): 436-438.
14	严立冬, 桂卉, 杨卓顺, 等. 上调细胞周期相关蛋白-1的表达对脑胶质瘤U251细胞的增殖和迁移能力的影响[J]. 医学研究生学报, 2018,31(1): 13-18.
15	CARDANO M, TRIBIOLI C, PROSPERI E. Targeting proliferating cell nuclear antigen (PCNA) as an effective strategy to inhibit tumor cell proliferation[J]. Curr. Cancer Drug Targets, 2020, 20(4): 240-252.
16	LIU H, GUO D, SHA Y, et al.. ANXA7 promotes the cell cycle, proliferation and cell adhesion-mediated drug resistance of multiple myeloma cells by up-regulating CDC5L[J]. Aging (Albany NY), 2020, 12(11): 11100-11115.
17	王彦秋. 冬凌草甲素联合顺铂对宫颈癌SiHa细胞凋亡及FOXL2、Ki67表达的影响[J]. 实用药物与临床, 2018, 21(5): 502-507.
18	黄鹏翀, 李晨辉, 王焱. 氟尿嘧啶植入剂对宫颈癌Hela细胞增殖和凋亡的影响[J]. 癌症进展, 2019, 17(11): 1275-1278.
19	陈萌萌, 王芳, 潘渊婷,等. 兔源抗凋亡蛋白Bcl-2的表达,抗体的制备及初步应用[J]. 江苏农业学报, 2019, 35(6): 1397-1401.
20	石金凤, 罗尧尧, 李佳鑫,等. 雷公藤甲素单用及联合用药抗肿瘤的作用及机制研究进展[J]. 中国中药杂志, 2019,44(16): 3391-3398.
21	LI Y, LV Z, ZHANG S, et al.. Genetic fate mapping of transient cell fate reveals N-cadherin activity and function in tumor metastasis[J]. Dev. Cell., 2020, 54(5): 593-607.
22	QUAN Y, ZHANG X, BUTLER W, et al.. The role of N-cadherin/c-Jun/NDRG1 axis in the progression of prostate cancer[J]. Int. J. Biol. Sci., 2021, 17(13): 3288-3304.
23	LI Y, ZHANG T, QIN S, et al.. Effects of UPF1 expression on EMT process by targeting E‑cadherin, N‑cadherin, Vimentin and Twist in a hepatocellular carcinoma cell line[J]. Mol. Med. Rep., 2019, 19(3): 2137-2143.
24	沈庆林, 彭敏, 章必成,等. 微小RNA-138通过调控上皮间质转化抑制乳腺癌侵袭和迁移的机制研究[J]. 中国医师进修杂志, 2019, 42(1): 42-46.

组别	Ki-67/GAPDH值	PCNA/GAPDH值	克隆形成率/%
对照组（n=18）	1.55±0.24	1.44±0.22	80.14±7.90
褪黑素组（n=18）	1.30±0.22^*	1.15±0.21^*	67.24±7.41^*
顺铂组（n=18）	0.87±0.12^*#	0.52±0.10^*#	31.20±5.17^*#
联合组（n=18）	0.52±0.09^*#&	0.32±0.09^*#&	10.90±5.00^*#&
F	116.806	179.604	444.803
P	<0.001	<0.001	<0.001

组别	Ki-67/GAPDH值	PCNA/GAPDH值	克隆形成率/%
对照组（n=18）	1.55±0.24	1.44±0.22	80.14±7.90
褪黑素组（n=18）	1.30±0.22^*	1.15±0.21^*	67.24±7.41^*
顺铂组（n=18）	0.87±0.12^*#	0.52±0.10^*#	31.20±5.17^*#
联合组（n=18）	0.52±0.09^*#&	0.32±0.09^*#&	10.90±5.00^*#&
F	116.806	179.604	444.803
P	<0.001	<0.001	<0.001

组别	Bcl-2/GAPDH值	Bax/GAPDH值	凋亡率（%）
对照组（n=18）	1.30±0.21	0.11±0.04	8.21±2.35
褪黑素组（n=18）	1.10±0.11^*	0.67±0.14^*	17.99±2.90^*
顺铂组（n=18）	0.72±0.10^*#	1.12±0.21^*#	48.36±5.01^*#
联合组（n=18）	0.58±0.08^*#&	1.39±0.25^*#&	69.47±6.75^*#&
F	109.851	176.803	672.281
P	<0.001	<0.001	<0.001

组别	Bcl-2/GAPDH值	Bax/GAPDH值	凋亡率（%）
对照组（n=18）	1.30±0.21	0.11±0.04	8.21±2.35
褪黑素组（n=18）	1.10±0.11^*	0.67±0.14^*	17.99±2.90^*
顺铂组（n=18）	0.72±0.10^*#	1.12±0.21^*#	48.36±5.01^*#
联合组（n=18）	0.58±0.08^*#&	1.39±0.25^*#&	69.47±6.75^*#&
F	109.851	176.803	672.281
P	<0.001	<0.001	<0.001

组别	E-cadherin/GAPDH值	N-cadherin/GAPDH值	Vimentin/GAPDH值	细胞24 h迁移率（%）
对照组（n=18）	1.10±0.15	0.57±0.08	0.41±0.08	62.50±7.14
褪黑素组（n=18）	0.98±0.12^*	0.77±0.14^*	0.60±0.10^*	50.36±5.54^*
顺铂组（n=18）	0.71±0.09^*#	1.01±0.11^*#	0.89±0.11^*#	38.14±5.01^*#
联合组（n=18）	0.50±0.08^*#&	1.20±0.20^*#&	1.07±0.12^*#&	18.79±5.00^*#&
F	102.012	69.841	145.385	54.434
P	<0.001	<0.001	<0.001	<0.001

Effects of Melatonin Combined with Cisplatin on Proliferation, Apoptosis and Invasion of Cervical Cancer HeLa Cells

RichHTML

PDF

Knowledge

Abstract

Cite this article

share this article

Figures/Tables 7

References 24

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	Lipei GUO, Qunchang ZHANG, Xin CAO, Xiuling ZHANG. Research on CPEB1 Reversing Chemoresistance of Ovarian Cancer Cells by Inhibiting Epithelial-mesenchymal Transition [J]. Current Biotechnology, 2026, 16(1): 205-212.
[2]	Ce JIANG, Yi LIU, Yalei ZHAO, Xiangrong CHANG. Effect of miR-5589-5p on Apoptosis and Autophagy of Hepatocellular Carcinoma Cells by Targeting FOXK1 [J]. Current Biotechnology, 2025, 15(6): 1086-1093.
[3]	Lina ZHU, Zhiling SONG. Autophagy and Apoptosis: Interactions and Their Role in Disease [J]. Current Biotechnology, 2025, 15(4): 622-626.
[4]	Geyemuri WU, Jianqiang WU. Anti-tumor Effects of Gentian Violet [J]. Current Biotechnology, 2025, 15(2): 226-233.
[5]	Yanjie WANG, Bo QIU. The Role and Research Progress of Gene P53 in Osteosarcoma [J]. Current Biotechnology, 2025, 15(2): 241-246.
[6]	Xu ZHU, Yingnan ZHANG, Jinfa MA, Lihong SHI. The Role of Ptbp1 in T Cell Acute Lymphoblastic Leukemia Mice [J]. Current Biotechnology, 2025, 15(2): 341-348.
[7]	Xuan ZHAO, Limei REN, Xiaoru WANG, Guangxin HAN, Dandan GU, Yasen YAO, Yonghao QI. Effects of siRNA Targeting to Interfere with the Expression of TRAF6 on the Proliferation and Apoptosis of Lung Cancer Cells [J]. Current Biotechnology, 2024, 14(5): 875-881.
[8]	Beibei LI, Jianqiang WU. Research Progress of Fas-mediated Non-apoptotic Signaling in Tumor Cells [J]. Current Biotechnology, 2024, 14(3): 406-412.
[9]	Mingjiao ZHANG, Jiefu ZHU, Xiongfei WU. Cell Death in Cisplatin-induced Kidney Injury [J]. Current Biotechnology, 2023, 13(5): 718-724.
[10]	Ying TANG, Jianqiang WU. Anti-tumor Effects of Phenylethanoid Glycosides Deprived from Cistanche deserticola [J]. Current Biotechnology, 2023, 13(3): 399-405.
[11]	Jingyi ZHANG, Xue JIANG, Siyu MA, Zhichao FENG, Yang YI, Chen MA, Yifei SONG, Fei XIE. Research Progress on the Protective Effects of Hydrogen Gas on Traumatic Brain Injury [J]. Current Biotechnology, 2023, 13(2): 234-239.
[12]	Yuzhen LI, Jiefu ZHU, Xiongfei WU. The Role of PIM1 Kinase in Cisplatin-induced Acute Kidney Injury [J]. Current Biotechnology, 2023, 13(2): 298-304.
[13]	Wanling HUANG, Wenqi ZHU, Nini GUO, Nan WANG, Qian REN, Xiaotong MA. Effects of NRG4 on Proliferation, Apoptosis and Cell Cycle of Acute Myeloid Leukemia Cells [J]. Current Biotechnology, 2023, 13(2): 305-310.
[14]	Liqiang DONG, Bin WANG, Shi SU, Dongqi LIU. Progress on Celastrol in Anti-tumor Effects and Mechanism [J]. Current Biotechnology, 2023, 13(1): 77-82.
[15]	Shibo WANG, Jinjuan LIU. Study on Antioxidant Activity and Inhibitory Effect of Banana Peel on HepG2 Cells [J]. Current Biotechnology, 2023, 13(1): 140-145.